PA

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Patterson MC et al. – Miglustat stabilized neurological disease progression in pediatric patients with Niemann–Pick disease type C, with comparable safety and tolerability to that observed in adults and juveniles.

Exclusive Author Commentary
Marc C. Patterson, 10/26/09

Only two therapeutic studies have been performed in human Niemann-Pick disease, type C (NPC). The first (Neurology 1993;43:61-64) examined the effect of cholesterol-lowering agents on hepatic and plasma cholesterol levels. Although the levels of cholesterol were reduced to varying degrees, subsequent follow up showed no evidence of therapeutic benefit. The second study in NPC was the trial of miglustat, which was the first to suggest that a drug could modify the course of human NPC as had been shown in animal models. The pediatric arm of this study was uncontrolled, but showed similar trends in outcome measures to the controlled study which enrolled patients over 12 years of age. Thus, miglustat may slow disease progression in NPC. In the short to medium term, combination therapy with miglustat and agents acting via different mechanisms may yield the best results. Curative therapy for NPC will require approaches that correct the primary defect, and must be considered a long term goal at present.

Today in Neurology...keeping you current

Migraine and Functional Impairment
CNS Drugs, 12/11/09

Mediterranean diet and cognitive function in older adults
Current Opinion in Clinical Nutrition & Metabolic Care, 12/11/09

Withanamides in Withania somnifera fruit protect PC-12 cells from beta-amyloid responsible for Alzheimer's disease
Phytotherapy Research, 12/11/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address